^
    Back
    Association details:
    Biomarker:BCR-ABL1 T315I
    Cancer:Leukemia
    Drug:Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) +
    Scemblix (asciminib) (Bcr-abl tyrosine kinase inhibitor, STAMP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    ASH 2019
    Title:

    Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants

    Published date:
    11/06/2019
    Excerpt:
    Additionally, the combination of asciminib with ponatinib resulted in suppression of T315I-inclusive compound mutant resistant clones using in vitro mutagenesis screens and significantly prolonged survival compared to either single agent in an in vivo T315I-inclusive compound mutant mouse xenograft model.
    DOI:
    https://doi.org/10.1182/blood-2019-131781